Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study

NCT05266586 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT05266586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2022
Completion date
September 8, 2022
Enrollment
119 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, high cholesterol, hypercholesterolemia